Bioniche Life Sciences Inc. Launches Two New Animal Health Products in Canada

Bioniche Life Sciences Inc. (BNC.TO) (BNC.AX), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its Immunocidin™ canine oncology therapy and its Sin Susto™ canine calming agent are both being launched in Canada at the annual Ontario Veterinary Medical Association Conference this week. The conference takes place from January 23-26 in Toronto , Ontario.

Immunocidin™is based on the Company's proprietary mycobacterial cell wall technology, the same platform from which its Phase III product for human bladder cancer (Urocidin™) was derived. Immunocidin™is indicated as an immunotherapy for the intratumoral treatment of mixed mammary tumor and mammary adenocarcinoma in dogs. The product was launched in the U.S. in October, 2012.

Sin Susto™ - "without fear" - is an herbal calming product for dogs in chewable tablet form that was developed in collaboration with the University of Ottawa . The product is made from natural botanical ingredients and acts as an agonist at the Gamma-aminobutyric acid (GABA)A receptor site. GABA is the primary inhibitory chemical messenger in the brain. Sin Susto™ has been proven safe and effective, is highly palatable, is non-habit-forming and non-psychotic, and does not act as a tranquilizer.

"We believe that both of these products represent important additions to our growing companion animal product line," said Mr. Andrew Grant , President, Bioniche Animal Health (global). "Immunocidin™ does not require special handling and can be used by veterinarians in their own clinics, either alone or in combination with other therapies. Sin Susto™ offers a safe, effective, non-habit-forming alternative to traditional pharmaceuticals that are known to have significant side effects."
About Canine Cancer